- Thirty Madison is a New York-based healthcare platform founded in 2017 that specializes in virtual specialized care for various conditions, recently positioned as a key player in the telehealth market.
- In September 2025, Thirty Madison announced its acquisition by Remedy Meds in an all-stock transaction valued at over $500 million, following its previous merger with Nurx in February 2022.
- The acquisition will create a multi-brand platform that includes Remedy Meds, Keeps, Nurx, and Cove, enhancing access to treatments across men's, women's, and metabolic health.
- Sales teams should focus on Thirty Madison's offerings as they target consumers seeking accessible, personalized healthcare solutions, particularly in the growing telehealth sector, which is projected to expand significantly post-acquisition.
Engineering is the largest function at Thirty Madison with 98 employees, underscoring the company’s emphasis on building and maintaining its digital health products. Marketing and Product follows with 45 team members, while Business Management and Healthcare roles account for 41 and 36 employees, respectively. Finance and Administration (29), Operations (18), Sales and Support (16), Information Technology (14), and Human Resources (12) round out the core groups, with an additional 21 employees classified under Other. This distribution points to a technology-driven company supported by strong business, clinical, and operational teams.
Thirty Madison’s workforce is geographically diverse, though it remains concentrated in major U.S. cities. Approximately 100 employees are based in New York, reflecting the company’s headquarters presence. The remaining staff are spread across hubs such as San Francisco (19), Houston (12), Los Angeles (6), and several mid-sized markets like Columbus, Denver, Missouri City, Boston, and Seattle. A significant segment (171 employees) works remotely or in other locations, suggesting a flexible approach to talent placement.
